287 Can HE4 replace CA 125 as a biomarker in ovarian cancer? | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article info

Ovarian cancer

287 Can HE4 replace CA 125 as a biomarker in ovarian cancer?

Free

Authors

A Ranjan AIIMS, Delhi, Lab Oncology, Delhi, India PubMed articles Google scholar articles
H Dubey AIIMS, Delhi, Lab Oncology, Delhi, India PubMed articles Google scholar articles
P Tanwar AIIMS, Delhi, Lab Oncology, Delhi, India PubMed articles Google scholar articles

Citation

Ranjan A, Dubey H, Tanwar P

287 Can HE4 replace CA 125 as a biomarker in ovarian cancer?

International Journal of Gynecologic Cancer 2021;31:A222-A223.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.